Lappoxo (Omeprazole)

Omeprazole blocks the H+/K+ ATPase enzyme, also known as the gastric proton pump, on the surface of parietal cells in the stomach. This irreversible inhibition stops the final step of acid production, leading to a sustained increase in gastric pH and reduced acid secretion, which alleviates symptoms and allows mucosal healing.

The appropriate dose of Lappoxo is determined by the prescribing healthcare professional based on the specific indication, patient age, renal function and other clinical factors. Dosage forms and strengths are selected to achieve optimal acid suppression while minimizing potential adverse effects.

Safety data for omeprazole in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will evaluate individual circumstances before prescribing Lappoxo to pregnant or nursing patients.

To request Lappoxo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Lappoxo (omeprazole) belongs to the proton pump inhibitor class, which provides more potent and longer‑lasting acid suppression than H2‑receptor antagonists such as ranitidine. Compared with newer PPIs, omeprazole has a well‑established efficacy and safety profile, though individual response and drug‑interaction potential may vary.

Lappoxo should be stored at room temperature, preferably below 25 °C. Keep the tablets in the original packaging to protect them from moisture and light. Do not store in a bathroom or near a heat source, and keep out of reach of children.

Lappoxo is taken orally, usually as a whole tablet swallowed with water. It is generally recommended to take the dose before a meal, often in the morning, unless the prescriber advises a different schedule based on the therapeutic indication.

Serious but rare risks include Clostridioides difficile‑associated colitis, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome or toxic epidermal necrolysis, and acute interstitial nephritis. Patients should seek immediate medical attention if they experience persistent diarrhoea, rash, swelling, or signs of kidney dysfunction.

Lappoxo is contraindicated in patients with known hypersensitivity to omeprazole or any component of the formulation. Caution is advised for individuals with severe liver disease, those taking medications that have major interactions (e.g., clopidogrel), and patients with a history of fractures or osteoporosis when used long‑term.